<DOC>
	<DOCNO>NCT01467531</DOCNO>
	<brief_summary>This single-center , two-cohort , three-period study healthy adult subject . Approximately 16 healthy subject enrol Cohort 1 provide data 14 evaluable subject . Approximately 12 healthy subject enrol Cohort 2 provide data 10 evaluable subject . Subjects screen visit within 30 day prior first dose study drug , three treatment period , follow-up visit 7-14 day last dose study drug . There washout period Period 1 Period 2 washout Period 2 Period 3 . Day 1 Period 3 start day last day Period 2 . The study conduct out-patient basis except day serial pharmacokinetic sample safety assessment schedule .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics Safety GSK1265744 Rilpivirine Dolutegravir Rilpivirine Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>AST , ALT , alkaline phosphatase bilirubin less equal 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator feel find unlikely introduce additional risk factor interfere study procedure . Male female 18 55 year age inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . Male subject female partner childbearing potential must agree use one contraception method list protocol . Body weight great equal 50 kg male 45 kg female BMI within range 18.5 31.0 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define protocol . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive urine hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . History regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>HIV , GSK1265744 , GSK1349572 , dolutegravir , rilpivirine , drug interaction , pharmacokinetics</keyword>
</DOC>